-
Article
Open AccessEuropean LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. Another goal is achieving a st...
-
Article
Erratum: Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
Correction to: Leukemia (2017) 31, 829–836. doi: 10.1038/leu.2017.9; Published online 11 January 2017 Following the publication of this article, the authors noted that family name of Susanne Sausselele was mis...
-
Article
Open AccessAssessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n=400) could be optimized by doubling the dose (n=420), adding interferon (IFN) (n=430) or cytar...
-
Article
Open AccessAbstracts from the 3rd Conference on Aneuploidy and Cancer: Clinical and Experimental Aspects
-
Article
Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations
Ruxolitinib is an oral Janus-activated kinase 1 (JAK1)/JAK2 inhibitor approved for the treatment of patients with myelofibrosis based on the results of two randomized clinical trials. However, discordant indic...
-
Article
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
It is unknown, why only a minority of chronic myeloid leukemia (CML) patients sustains treatment free remission (TFR) after discontinuation of tyrosine kinase inhibitor (TKI) therapy in deep molecular remissio...
-
Article
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry
The European Treatment and Outcome Study (EUTOS) population-based registry includes data of all adult patients newly diagnosed with Philadelphia chromosome-positive and/or BCR-ABL1+ chronic myeloid leukemia (C...
-
Article
Prof. Thomas Büchner (22 September 1934–5 August 2016)—A leading European hematologist and AML trialist
-
Article
Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia
-
Article
Open AccessEuropean LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors (TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast, adverse events (AEs) are often r...
-
Article
Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia
We randomized 3375 adults with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome to test whether increasingly intensive chemotherapies assigned at study-entry and analyzed on a...
-
Article
Open AccessSecondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
Treatment of chronic myeloid leukemia (CML) has been profoundly improved by the introduction of tyrosine kinase inhibitors (TKIs). Long-term survival with imatinib is excellent with a 8-year survival rate of ∼...
-
Article
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both
The Philadelphia-negative myeloproliferative neoplasms (MPNs) are clonal disorders involving hematopoietic stem and progenitor cells and are associated with myeloproliferation, splenomegaly and constitutional ...
-
Article
Open AccessLong-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment
Tyrosine kinase inhibitors represent today’s treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective ra...
-
Article
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia
In patients with chronic myeloid leukemia (CML), first-line imatinib treatment leads to 8-year overall survival (OS) probabilities above 80%. Many patients die of reasons unrelated to CML. This work tackled th...
-
Article
Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia
A minority of chronic myeloid leukemia (CML) patients is capable of successfully discontinuing imatinib. Treatment modalities to increase this proportion are currently unknown. Here, we assessed the role of in...
-
Article
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries
This population-based registry was designed to provide robust and updated information on the characteristics and the epidemiology of chronic myeloid leukemia (CML). All cases of newly diagnosed Philadelphia po...
-
Article
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
Tyrosine kinase inhibitors (TKI) have changed the natural course of chronic myeloid leukemia (CML). With the advent of second-generation TKI safety and efficacy issues have gained interest. The randomized CML ...
-
Article
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
The discovery of somatic mutations, primarily JAK2V617F and CALR, in classic BCR-ABL1-negative myeloproliferative neoplasms (MPNs) has generated interest in the development of molecularly targeted therapies, whos...
-
Article
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
Early assessment of response at 3 months of tyrosine kinase inhibitor treatment has become an important tool to predict favorable outcome. We sought to investigate the impact of relative changes of BCR-ABL tra...
